|Trade Names:||Bortezomib™, Velcade™, and Neomib™|
|Chemical Compound:||BXCL101, Bortezomib, PS-341|
|Synonyms:||PS-341, LDP 341, LDP-341, LDP341,
MLN341, ps 341, PS 341, 341
|Pharmaceutical Companies:||BioXcel Therapeutics,
previously Millennium Pharmaceuticals
|NF2 Trial Availability||Initially Proposed to
start in the US before 2018
|Legal Status:||℞ - Prescription Only|
|Administered By:||Intravenous (IV) or Port|
|Tumor Target:||Schwannoma and Meningioma||Protein Target:||Proteasome Inhibitor|
|NF2 Trials||Active, Not Recruiting: University of Virginia|
Chemical Compound BXCL101 was designed by Myogenics Pharmecuticles initially under treatment called Velcade™ in the United Kingdom (UK). It proved to have help Multiple Myeloma and Mantle Cell Lymphoma. In 2006, Velcade™ was rejected by the UK's 'National Institute for Health and Care Excellence' (NICE), an executive non-departmental public body of the Department of Health in the United Kingdom due to cost, not an issue of effectiveness.
Bortezomib has been in trial in the United States for Multiple Myeloma and Mantle Cell Lymphoma. Like the UK trials, the trials listed under ClinicalTrials.org, are Combination trials which include Dexamethasone
"Bortezomib mainly causes sensory peripheral neuropathy, but severe motor peripheral neuropathy also has been reported. In the phase III trial, peripheral neuropathy occurred in thirty-six percent (36%) of patients receiving bortezomib and nine percent (9%) of patients receiving dexamethasone. About 8% of patients discontinued bortezomib therapy because of peripheral neuropathy."
"Patients receiving bortezomib should be monitored for manifestations of neuropathy (eg, burning sensation, hyperesthesia, hypoesthesia, paresthesia, discomfort, neuropathic pain). Dose and/or frequency of administration of bortezomib should be adjusted in patients who experience new-onset or exacerbation of peripheral neuropathy."
"Hypoglycemia and hyperglycemia have been reported in patients with diabetes mellitus who received bortezomib concomitantly with oral antidiabetic agents. If bortezomib is used concomitantly with oral antidiabetic agents, blood glucose concentrations should be monitored carefully and dosage of the antidiabetic agent adjusted as necessary."
"Potential interaction (increased risk of hypotension) when bortezomib is used with drugs that can cause hypotension. Dosage adjustment of hypotensive agents may be necessary."
"Among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation, daratumumab combined with bortezomib, melphalan, and prednisone resulted in a lower risk of disease progression or death than the same regimen without daratumumab.